Letter to the Editor: Remission of Graves' Disease After Initiation of Ocrelizumab in Patients with Multiple Sclerosis.

Autor: Casany-Fernandez R; Department of Endocrinology and Nutrition, Hospital Clinico Universitario de Valencia, Valencia, Spain., Gascon-Gimenez F; Multiple Sclerosis Unit, Department of Neurology, Hospital Clinico Universitario de Valencia, Valencia, Spain., Matarredona Solaz EJ; Department of Endocrinology and Nutrition, Hospital Clinico Universitario de Valencia, Valencia, Spain., Pardo Lozano F; Department of Endocrinology and Nutrition, Hospital Clinico Universitario de Valencia, Valencia, Spain., Dominguez-Moran JA; Multiple Sclerosis Unit, Department of Neurology, Hospital Clinico Universitario de Valencia, Valencia, Spain., Ferri Ciscar J; Department of Endocrinology and Nutrition, Hospital Clinico Universitario de Valencia, Valencia, Spain., Real Collado JT; Department of Endocrinology and Nutrition, Hospital Clinico Universitario de Valencia, Valencia, Spain.; INCLIVA (Instituto de Investigacion Sanitaria), Valencia, Spain.; CIBERDEM (Centro de investigación biomedica en red de diabetes y enfermedades metabólicas asociadas), Madrid, Spain.

Publikováno v: Thyroid : official journal of the American Thyroid Association [Thyroid] 2023 Feb; Vol. 33 (2), pp. 267-269. Date of Electronic Publication: 2022 Dec 13.